Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05935085 · ClinicalTrials.gov registry record · Phase 2
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
A Phase 2 study, sponsored by AnaptysBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
NCT05935085 is a Phase 2 study that was terminated before completion, run by AnaptysBio. The registered enrollment target is 201 participants.
The verdict
NCT05935085, a Phase 2 study, was terminated before completion, sponsored by AnaptysBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Interventions
- DRUG Placebo
- DRUG ANB032
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2023-06-13 |
| Est. Completion | 2025-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05935085
The ClinicalTrials.gov registry entry for NCT05935085 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AnaptysBio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05935085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05935085 about?
NCT05935085 is a clinical study titled "This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).". This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
What is the current status of trial NCT05935085?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2023-06-13. Estimated completion is 2025-01-07.
What interventions are being tested in trial NCT05935085?
The interventions under investigation include: Placebo (DRUG), ANB032 (DRUG).
Who is sponsoring clinical trial NCT05935085?
This trial is sponsored by AnaptysBio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.